Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

INTRODUCTION: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who had serio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasaka, Masahiro, Yokota, Hiroyuki, Suzuki, Michiyasu, Asakura, Hidesaku, Yamane, Teiichi, Ogi, Yukako, Ochiai, Kaori, Nakayama, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237558/
https://www.ncbi.nlm.nih.gov/pubmed/32152956
http://dx.doi.org/10.1007/s40119-020-00165-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237558/
https://www.ncbi.nlm.nih.gov/pubmed/32152956
http://dx.doi.org/10.1007/s40119-020-00165-8

Ejemplares similares